Rein Therapeutics (RNTX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for July 20, 2026, and will be held virtually, allowing shareholders to vote and submit questions online.

• Shareholders of record as of May 21, 2026, are eligible to vote on key proposals, including director elections, an amendment to increase authorized shares, auditor ratification, and executive compensation.

• Proxy materials are available online, and shareholders are encouraged to vote electronically or by mail.

Voting matters and shareholder proposals

• Election of two Class III directors to serve until the 2029 annual meeting.

• Approval of an amendment to increase authorized common stock from 100 million to 200 million shares.

• Ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for 2026.

• Advisory vote to approve named executive officer compensation.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• The board is classified into three staggered classes, with two Class III directors up for election.

• Majority of board members are independent, except the CEO.

• Board committees (Audit, Compensation, Nominating/Governance) are composed of independent directors.

• Directors are expected to attend at least 75% of meetings and the annual meeting.

• Corporate governance guidelines, code of ethics, and policies on insider trading, anti-hedging, and clawbacks are in place.